Paper41234640
SARS-CoV-2 mRNA vaccine candidate encoding RBD chimera of Delta and Omicron variants: immunogenic potential and validation.
Shahsavandi S and 8 others. Iran J Microbiol, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. SARS-CoV-2 mRNA vaccine candidate encoding RBD chimera of Delta and Omicron variants: immunogenic potential and validation. Papers, record 41234640. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41234640
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- SARS-CoV-2 mRNA vaccine candidate encoding RBD chimera of Delta and Omicron variants: immunogenic potential and validation.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36423021 | The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. | Vaccines (Basel) | 2022 | https://conductscience.org/library/papers/36423021 | PubMed |
| 2 | 32884216 | Mutations in SARS-CoV-2 Leading to Antigenic Variations in Spike Protein: A Challenge in Vaccine Development. | J Lab Physicians | 2020 | https://conductscience.org/library/papers/32884216 | PubMed |
| 3 | 35717982 | Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. | Lancet | 2022 | https://conductscience.org/library/papers/35717982 | PubMed |
| 4 | 34859663 | Non-liver mRNA Delivery. | Acc Chem Res | 2022 | https://conductscience.org/library/papers/34859663 | PubMed |
| 5 | 32730807 | The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. | Cell | 2020 | https://conductscience.org/library/papers/32730807 | PubMed |
| 6 | 33013929 | Variations in SARS-CoV-2 Spike Protein Cell Epitopes and Glycosylation Profiles During Global Transmission Course of COVID-19. | Front Immunol | 2020 | https://conductscience.org/library/papers/33013929 | PubMed |
| 7 | 34181394 | Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. | ACS Nano | 2021 | https://conductscience.org/library/papers/34181394 | PubMed |
| 8 | 36917125 | The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties - an alarming global threat of a surge in COVID-19 cases again? | Int J Surg | 2023 | https://conductscience.org/library/papers/36917125 | PubMed |
| 9 | 35094366 | Delivery Strategies for mRNA Vaccines. | Pharmaceut Med | 2022 | https://conductscience.org/library/papers/35094366 | PubMed |
| 10 | 37779140 | Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. | Exp Mol Med | 2023 | https://conductscience.org/library/papers/37779140 | PubMed |
| 11 | 34645933 | Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization. | Commun Biol | 2021 | https://conductscience.org/library/papers/34645933 | PubMed |
| 12 | 39059371 | SARS-CoV-2 Omicron XBB lineage spike structures, conformations, antigenicity, and receptor recognition. | Mol Cell | 2024 | https://conductscience.org/library/papers/39059371 | PubMed |
| 13 | 32756549 | SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. | Nature | 2020 | https://conductscience.org/library/papers/32756549 | PubMed |
| 14 | 34914115 | Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. | J Med Virol | 2022 | https://conductscience.org/library/papers/34914115 | PubMed |
| 15 | 36677483 | Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion from Antibody Neutralisation in BNT162b2 Vaccine Recipients. | Microorganisms | 2023 | https://conductscience.org/library/papers/36677483 | PubMed |
| 16 | 34850635 | Chemistry of Lipid Nanoparticles for RNA Delivery. | Acc Chem Res | 2022 | https://conductscience.org/library/papers/34850635 | PubMed |
| 17 | 32698192 | Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. | Nature | 2020 | https://conductscience.org/library/papers/32698192 | PubMed |
| 18 | 16597622 | Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. | J Biol Chem | 2006 | https://conductscience.org/library/papers/16597622 | PubMed |
| 19 | 35051990 | Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. | Nat Med | 2022 | https://conductscience.org/library/papers/35051990 | PubMed |
| 20 | 37721934 | Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7. | PLoS Pathog | 2023 | https://conductscience.org/library/papers/37721934 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| LNPK | 80856 | PubTator's text mining | https://conductscience.org/library/genes/80856 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41234640
GET https://conductscience.org/api/papers/v1/41234640/references?page=2